Lista de obras - Satu Mustjoki - Dominio Público Uruguay

A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells

scientific article published on 22 April 2020

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

A novel class of somatic mutations in blood detected preferentially in CD8+ cells

artículo científico publicado en 2016

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

artículo científico publicado en 2009

A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease

scientific article published on 01 April 2019

ADA2 deficiency: clonal lymphoproliferation in a subset of patients

artículo científico publicado en 2018

Abstract 1169: Somatic MED12 mutations in hematological malignancies

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

artículo científico publicado en 2018

Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease

artículo científico publicado en 2014

Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia

artículo científico publicado en 2015

Acute lymphoblastic leukemia associated with RCSD1–ABL1 novel fusion gene has a distinct gene expression profile from BCR–ABL1 fusion

article

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

artículo científico publicado en 2020

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

artículo científico publicado en 2018

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia

scientific article published on 14 June 2007

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

artículo científico publicado en 2016

Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

artículo científico publicado en 2014

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

artículo científico publicado en 2017

Characterization of Bone Marrow Niche in Chronic Myeloid Leukemia Patients Identifies CXCL14 as a New Therapeutic Option

artículo científico publicado en 2023

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

scientific article published on 09 November 2020

Characterization of polydactyly chondrocytes and their use in cartilage engineering

scientific article published on 12 March 2019

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

artículo científico publicado en 2011

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

artículo científico publicado en 2009

Clonal hematopoiesis in patients with rheumatoid arthritis

scholarly article by Paula Savola et al published 26 July 2018 in Blood Cancer Journal

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

artículo científico publicado en 2011

Combined immunodeficiency and hypoglycemia associated with mutations in hypoxia upregulated 1.

artículo científico publicado en 2016

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myelo

artículo científico publicado en 2008

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

artículo científico publicado en 2020

Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes

artículo científico publicado en 2017

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

artículo científico publicado en 2017

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

artículo científico publicado en 2008

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

artículo científico publicado en 2014

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

artículo científico publicado en 2014

Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner

artículo científico publicado en 2017

Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes

artículo científico publicado en 2013

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

artículo científico publicado en 2017

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

artículo científico publicado en 2018

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

artículo científico publicado en 2017

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

artículo científico publicado en 2013

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions

artículo científico publicado en 2018

Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease

artículo científico publicado en 2019

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

artículo científico publicado en 2013

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling

artículo científico publicado en 2017

Drug-perturbation-based stratification of blood cancer

artículo científico publicado en 2017

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

artículo científico publicado en 2017

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

artículo científico publicado en 2014

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

artículo científico publicado en 2011

Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach

artículo científico publicado en 2017

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia.

artículo científico publicado en 2016

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2022

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia

artículo científico publicado en 2014

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.

artículo científico publicado en 2016

IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.

artículo científico publicado en 2015

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

artículo científico publicado en 2014

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

scientific article published on 11 January 2019

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

scholarly article by Oscar Brück et al published 20 June 2018 in Leukemia

Immune cell phenotype and functional defects in Netherton syndrome

scientific article published on 26 November 2018

Immune control in chronic myeloid leukemia

artículo científico publicado en 2017

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

artículo científico publicado en 2020

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

artículo científico publicado en 2019

Immunology and immunotherapy of chronic myeloid leukemia

artículo científico

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

artículo científico publicado en 2010

Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)

artículo científico publicado en 2014

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

artículo científico publicado en 2013

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

scientific article published on 15 April 2009

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

artículo científico publicado en 2013

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

artículo científico publicado en 2016

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

artículo científico publicado en 2013

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

artículo científico publicado en 2013

Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation.

artículo científico publicado en 2016

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

scientific article published on 21 November 2019

JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).

artículo científico publicado en 2008

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

artículo científico publicado en 2012

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

scientific article published on 17 June 2019

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

artículo científico publicado en 2016

Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia

artículo científico publicado en 2017

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

artículo científico publicado en 2017

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

artículo científico publicado en 2017

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

artículo científico publicado en 2009

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

artículo científico publicado en 2016

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

artículo científico publicado en 2021

Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies

artículo científico publicado en 2019

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

artículo científico publicado en 2010

Morphology antibody chromosome technique for determining phenotype and genetic status of the same cell

artículo científico

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

artículo científico publicado en 2020

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib

artículo científico publicado en 2017

Non-Ph variants in CML: guilty drivers?

artículo científico publicado en 2018

Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.

artículo científico publicado en 2014

Novel TMEM173 Mutation and the Role of Disease Modifying Alleles

artículo científico publicado en 2019

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

artículo científico publicado en 2014

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

artículo científico publicado en 2015

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

artículo científico publicado en 2013

Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia

scientific article published on 01 July 2008

PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma

scholarly article by Marjukka Pollari et al published November 2018 in Haematologica

Patient-customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

artículo científico publicado en 2018

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

artículo científico publicado en 2019

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

scientific article published on 11 July 2019

Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

artículo científico publicado en 2012

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

artículo científico publicado en 2016

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

artículo científico publicado en 2020

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

artículo científico publicado en 2010

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma

artículo científico publicado en 2020

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

artículo científico publicado en 2019

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

artículo científico publicado en 2020

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

artículo científico publicado en 2012

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

artículo científico publicado en 2016

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

artículo científico publicado en 2020

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL

scientific article published on 16 March 2020

STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

artículo científico publicado en 2013

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

artículo científico publicado en 2012

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

artículo científico publicado en 2016

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

artículo científico publicado en 2021

Sex bias in MHC I-associated shaping of the adaptive immune system.

artículo científico publicado en 2018

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

artículo científico

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.

artículo científico publicado en 2017

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

artículo científico publicado en 2017

Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry

artículo científico publicado en 2017

Somatic STAT3 mutations in large granular lymphocytic leukemia ⬇️

artículo científico publicado en 2012

Somatic STAT3 mutations in the Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia

artículo científico publicado en 2017

Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease

scientific article published on 07 May 2020

Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis.

artículo científico publicado en 2017

Spermidine/spermine N1-acetyltransferase activity associates with white blood cell count in myeloid leukemias

artículo científico publicado en 2014

Subclonal STAT3 mutations solidify clonal dominance

article published in 2019

Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms

artículo científico publicado en 2009

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma

artículo científico publicado en 2022

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma

scholarly article by Suvi-Katri Leivonen et al published February 2019 in Haematologica

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia

artículo científico publicado en 2018

Terminal deletion of 11q with significant late-onset combined immune deficiency

artículo científico publicado en 2014

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients

artículo científico publicado en 2017

The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia

artículo científico publicado en 2014

The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses

artículo científico

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Therapy de-escalation before stopping in chronic myeloid leukaemia

scientific article published on 11 June 2019

Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia

artículo científico publicado en 2019

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

artículo científico publicado en 2017

Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations

artículo científico

VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells

artículo científico publicado en 2002

Lista de obras de Satu Mustjoki

A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

A novel class of somatic mutations in blood detected preferentially in CD8+ cells

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease

ADA2 deficiency: clonal lymphoproliferation in a subset of patients

Abstract 1169: Somatic MED12 mutations in hematological malignancies

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease

Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia

Acute lymphoblastic leukemia associated with RCSD1–ABL1 novel fusion gene has a distinct gene expression profile from BCR–ABL1 fusion

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

Characterization of Bone Marrow Niche in Chronic Myeloid Leukemia Patients Identifies CXCL14 as a New Therapeutic Option

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Characterization of polydactyly chondrocytes and their use in cartilage engineering

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Clonal hematopoiesis in patients with rheumatoid arthritis

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Combined immunodeficiency and hypoglycemia associated with mutations in hypoxia upregulated 1.

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myelo

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner

Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions

Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling

Drug-perturbation-based stratification of blood cancer

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia.

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.

IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

Immune cell phenotype and functional defects in Netherton syndrome

Immune control in chronic myeloid leukemia

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Immunology and immunotherapy of chronic myeloid leukemia

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation.

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity